Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/124277
Title: Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG)
Author: Kovacs, Gabor G.
Xie, Sharon X.
Lee, Edward B.
Robinson, John L.
Caswell, Carrie
Irwin, David J.
Toledo, Jon B.
Johnson, Victoria
Smith, Douglas H.
Alafuzoff, Irina
Attems, Johannes
Bencze, Janos
Bieniek, Kevin F.
Bigio, Eileen H.
Bodi, Istvan
Budka, Herbert
Dickson, Dennis W.
Dugger, Brittany N.
Duyckaerts, Charles
Ferrer, Isidro (Ferrer Abizanda)
Forrest, Shelley L.
Gelpi, Ellen
Gentleman, Stephen M.
Giaccone, Giorgio
Grinberg, Lea T.
Halliday, Glenda M.
Hatanpaa, Kimmo J.
Hof, Patrick R.
Hofer, Monika
Hortobagyi, Tibor
Ironside, James W.
King, Andrew
Kofler, Julia
Kövari, Enikö
Kril, Jillian J.
Love, Seth
Mackenzie, Ian R.
Mao, Qinwen
Matej, Radoslav
Mclean, Catriona
Muñoz, David G.
Murray, Melissa E.
Neltner, Janna
Nelson, Peter T.
Ritchie, Diane
Rodriguez, Roberta D.
Rohan, Zdenek
Rozemüller, Annemieke
Sakai, Kenji
Schultz, Christian
Seilhean, Danielle
Smith, Vanessa
Tacik, Pawel
Takahashi, Hitoshi
Takao, Masaki
Thal, Dietmar Rudolf
Weis, Serge
Wharton, Stephen B.
White III, Charles L.
Woulfe, John M.
Yamada, Masahito
Trojanowski, John Q.
Keywords: Malalties del sistema nerviós
Envelliment
Nervous system diseases
Aging
Issue Date: 1-Jul-2017
Publisher: Oxford University Press
Abstract: Aging-related tau astrogliopathy (ARTAG) is a recently introduced terminology. To facilitate the consistent identification of ARTAG and to distinguish it from astroglial tau pathologies observed in the primary frontotemporal lobar degeneration tauopathies we evaluated how consistently neuropathologists recognize (1) different astroglial tau immunoreactivities, including those of ARTAG and those associated with primary tauopathies (Study 1); (2) ARTAG types (Study 2A); and (3) ARTAG severity (Study 2B). Microphotographs and scanned sections immunostained for phosphorylated tau (AT8) were made available for download and preview. Percentage of agreement and kappa values with 95% confidence interval (CI) were calculated for each evaluation. The overall agreement for Study 1 was > 60% with a kappa value of 0.55 (95% CI 0.433-0.645). Moderate agreement (> 90%, kappa 0.48, 95% CI 0.457-0.900) was reached in Study 2A for the identification of ARTAG pathology for each ARTAG subtype (kappa 0.37-0.72), whereas fair agreement (kappa 0.40, 95% CI 0.341-0.445) was reached for the evaluation of ARTAG severity. The overall assessment of ARTAG showed moderate agreement (kappa 0.60, 95% CI 0.534-0.653) among raters. Our study supports the application of the current harmonized evaluation strategy for ARTAG with a slight modification of the evaluation of its severity.
Note: Versió postprint del document publicat a: https://doi.org/10.1093/jnen/nlx041
It is part of: Journal of Neuropathology and Experimental Neurology, 2017, vol. 76, num. 7, p. 605-619
URI: http://hdl.handle.net/2445/124277
Related resource: https://doi.org/10.1093/jnen/nlx041
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
KovacsGG.pdf233.93 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.